CervoMed to Participate in Upcoming Investor Conferences
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in two upcoming investor conferences in September 2025.
The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, from 2:00 to 2:30 PM ET, with both presentation and one-on-one investor meetings. Additionally, CervoMed will participate in Morgan Stanley's 23rd Annual Global Healthcare Conference from September 8-10, 2025, featuring one-on-one investor meetings.
CervoMed Inc. (NASDAQ: CRVO), società in fase clinica che sviluppa trattamenti per disturbi neurologici legati all'età, ha annunciato la propria partecipazione a due conferenze per investitori previste a settembre 2025.
La società terrà una presentazione al H.C. Wainwright 27th Annual Global Investment Conference l'8 settembre 2025, dalle 14:00 alle 14:30 ET, comprensiva di presentazione e incontri one-to-one con investitori. Inoltre, CervoMed prenderà parte al Morgan Stanley's 23rd Annual Global Healthcare Conference dall'8 al 10 settembre 2025, con incontri individuali programmati con investitori.
CervoMed Inc. (NASDAQ: CRVO), una compañía en fase clínica que desarrolla tratamientos para trastornos neurológicos relacionados con la edad, ha anunciado su participación en dos conferencias para inversores en septiembre de 2025.
La compañía presentará en el H.C. Wainwright 27th Annual Global Investment Conference el 8 de septiembre de 2025, de 2:00 a 2:30 PM ET, con presentación y reuniones individuales con inversores. Además, CervoMed participará en el Morgan Stanley's 23rd Annual Global Healthcare Conference del 8 al 10 de septiembre de 2025, con reuniones one-on-one con inversores.
CervoMed Inc. (NASDAQ: CRVO), 연령 관련 신경계 질환 치료제를 개발하는 임상 단계 기업이 2025년 9월에 개최되는 두 건의 투자자 컨퍼런스에 참여한다고 발표했습니다.
회사는 H.C. Wainwright 27th Annual Global Investment Conference에서 2025년 9월 8일 동부시간 오후 2시부터 2시 30분까지 발표 및 일대일 투자자 미팅을 진행합니다. 또한 CervoMed는 2025년 9월 8일부터 10일까지 열리는 Morgan Stanley's 23rd Annual Global Healthcare Conference에도 참여하여 일대일 투자자 미팅을 진행할 예정입니다.
CervoMed Inc. (NASDAQ: CRVO), une entreprise en phase clinique développant des traitements pour les troubles neurologiques liés à l'âge, a annoncé sa participation à deux conférences investisseurs prévues en septembre 2025.
La société présentera au H.C. Wainwright 27th Annual Global Investment Conference le 8 septembre 2025, de 14h00 à 14h30 ET, avec une présentation et des entretiens individuels avec des investisseurs. De plus, CervoMed participera au Morgan Stanley's 23rd Annual Global Healthcare Conference du 8 au 10 septembre 2025, avec des réunions one‑on‑one prévues avec des investisseurs.
CervoMed Inc. (NASDAQ: CRVO), ein klinisch tätiges Unternehmen, das Behandlungen für altersbedingte neurologische Erkrankungen entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird am H.C. Wainwright 27th Annual Global Investment Conference am 8. September 2025 von 14:00 bis 14:30 Uhr ET präsentieren, einschließlich Präsentation und Einzelgesprächen mit Investoren. Darüber hinaus wird CervoMed vom 8. bis 10. September 2025 am Morgan Stanley's 23rd Annual Global Healthcare Conference teilnehmen und dort Einzelgespräche mit Investoren führen.
- None.
- None.
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in the following investor conferences during the month of September:
H.C. Wainwright 27th Annual Global Investment Conference
Format: Presentation & 1x1 Investor Meetings
Presentation Date: Monday, September 8, 2025
Presentation Time: 2:00 – 2:30 PM ET
Webcast: https://journey.ct.events/view/b01e16a4-43fd-41b8-b4c0-2815213f7950
Morgan Stanley’s 23rd Annual Global Healthcare Conference
Format: 1x1 Investor Meetings
Conference Dates: September 8-10, 2025
The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.
About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.
Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579
FAQ
When is CervoMed (NASDAQ: CRVO) presenting at the H.C. Wainwright Conference?
How can investors access CervoMed's H.C. Wainwright conference presentation?
What type of company is CervoMed (CRVO)?
Which investor conferences will CervoMed attend in September 2025?
